Navigation Links
Mouse model for mesothelioma reproduces human disease
Date:3/10/2008

Scientists have established a mouse model for human malignant mesothelioma (MM) that will provide valuable insight into cancer development and progression along with new directions for design of therapeutic strategies. The research, published by Cell Press in the March issue of Cancer Cell, may eventually lead to a substantially improved outlook for patients with this devastating disease.

MM is an aggressive cancer originating from the mesothelial lining of the pleural cavity. MM is associated with asbestos exposure and is characterized by a long latency period between exposure and disease onset. Chemotherapy can sometimes lead to improvement of overall survival but there is no cure for MM and patients often succumb from the disease within a year of diagnosis. There is an urgent need for experimental models of MM that can be used to not only study the onset and progression of the disease, but also to serve as a model to select new combination therapies and targeted agents, says study leader, Dr. Anton Berns, from The Netherlands Cancer Institute.

In humans, MM has been associated with genetic lesions that result in the loss of Neurofibromatosis type 2 (NF2) and genetic lesions affecting RB and P53 pathways. Dr. Berns team investigated whether a range of conditional single or compound mutations in the Nf2, p53 and Rb pathways within the mesothelial lining of the thoracic cavity would cause MM in mice.

The researchers found that the vast majority of mice with conditional Nf2;Ink4a/Arf and Nf2;p53 mutations developed MM after a short latency period. The mouse MM tumors, which could be followed noninvasively through the use of bioluminescence imaging, closely resembled human MM. Interestingly, Nf2;Ink4a/Arf knockout mice had a more invasive cancer when compared with Nf2;p53 knockout mice. The researchers went on to show that the loss of Ink4a makes a substantial contribution to the poor clinical outcome of murine MM.

These results describe an excellent model system for investigating the molecular mechanisms that underlie MM. Our mouse models should be suitable to further dissect pathways critically important in mesothelioma development and progression and serve as invaluable tools to test new intervention strategies, concludes Dr. Berns. We have also derived a series of cell lines that reproduce the disease when grafted into the thoracic cavity. These may also facilitate design of better MM therapies.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Mouse study: Real-time imaging device may improve surgery for congenital colon disease
2. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
3. Mouse Model of Age-Related Macular Degeneration Developed
4. Gene Tweak Reverses Aging in Mouse Skin Cells
5. A longer-living, healthier mouse that could hold clues to human aging
6. Mouse mammary tumor virus can replicate in human cells
7. Mouse Study Gives Clues to Colitis
8. Mouse vision has a rhythm all its own
9. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
10. Liko Introduces New LowBase(TM) Model of Its Popular Golvo Mobile Lift
11. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The Patient ... Baltimore Health System, with the 2017 Ruth Ravich Patient Advocacy Award in ... patient advocates. DeVaro was honored with the award at The Beryl Institute’s annual ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... A Week of Addiction and Recovery Education, from April 24 to April 28, ... substance use disorders. , The mission of AWARE is to instill a ...
(Date:4/21/2017)... UK (PRWEB) , ... April 21, 2017 , ... ... for Enterprise in the category of International Trade, the UK’s most prestigious award ... international trade, which represents 95% of total revenues and has grown by a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Westside ... experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become one ... to help my numerous clients over the years with all their dental needs,” said ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology: